公开(公告)号：BR9508296A

公开(公告)日：1998-05-19

申请号：BR9508296

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  RENDENDACH-MULLER BEATRICE ,  LANSKY ANNEGRET ,  WICKE CARSTEN ,  TESCHENDORF HANS-JUERGEN ,  BACH ALFRED ,  UNGER LILIANE

IPC: C07D233/84 ,  A61K31/33 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/495 ,  A61K31/496 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D213/56 ,  C07D213/64 ,  C07D213/65 ,  C07D213/70 ,  C07D213/73 ,  C07D213/79 ,  C07D213/81 ,  C07D233/90 ,  C07D307/79 ,  C07D333/24 ,  C07D333/28 ,  C07D333/38 ,  C07D471/18

Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

公开(公告)号：BR9508295A

公开(公告)日：1998-01-13

申请号：BR9508295

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENDACH-MULLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JURGEN ,  WICKE KARSTEN

IPC: C07D277/22 ,  A61K31/425 ,  A61K31/426 ,  A61K31/433 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/496 ,  A61K31/54 ,  C07D277/20 ,  C07D277/32 ,  C07D277/36 ,  C07D277/42 ,  C07D285/12 ,  C07D285/125 ,  C07D285/135 ,  C07D417/12

Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.